Name: a&m impact
Price range: $

Publicaties internist-hematoloog mw. dr. F. de Boer

Factors and Considerations in No-Treatment Decisions in Patients With Key Hematological Malignancies: A Nationwide, Population-Based Study in the Netherlands
-een van de auteurs: internist-hematoloog mw. F. de Boer
Eur J Haematol. 2025 May;114(5):872-882. doi: 10.1111/ejh.14390. Epub 2025 Jan 29.
Impact of comorbidity on health-related quality of life in newly diagnosed patients with lymphoma or multiple myeloma: results from the PROFILES-registry
-een van de auteurs: internist-hematoloog mw. F. de Boer
Ann Hematol. 2024 Dec;103(12):5511-5525. doi: 10.1007/s00277-024-06006-1. Epub 2024 Sep 16.
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
-een van de auteurs: internist-hematoloog mw. F. de Boer
Blood. 2023 Sep 28;142(13):1131-1142. doi: 10.1182/blood.2023020195.
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
-een van de auteurs: internist-hematoloog mw. F. de Boer
EClinicalMedicine. 2023 Aug 29:63:102167. doi: 10.1016/j.eclinm.2023.102167. eCollection 2023 Sep
The CLL treatment infection model clinical prospective validation a part of the prevent-a-call trial
-een van de auteurs: internist-hematoloog mw. F. de Boer
Hemasphere. 2023 Aug; 7(Suppl ): e1432517. Published online 2023 Aug 8. doi: 10.1097/01.HS9.0000969420.14325.17
P619: Tracking disease parameters by MRD, CT and PET in first line CCL patients treated with fixed duration ibrutinib-venetoclax: interim analysis of the first 30 patients in HOVON 158?NEXT STEP Trial
-een van de auteurs: internist-hematoloog mw. F. de Boer
HemaSphere 7(S3):p e797861a, August 2023. | DOI: 10.1097/01.HS9.0000969380.79786.1a
Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
-een van de auteurs: internist-hematoloog mw. F. de Boer
Vaccines (Basel). 2023 Jul 4;11(7):1201. doi: 10.3390/vaccines11071201.
JAK-STAT signalling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL
-een van de auteurs: internist-hematoloog mw. F. de Boer
Mol Oncol. 2023 Jun;17(6):1112-1128. doi: 10.1002/1878-0261.13364. Epub 2023 Feb 13.
Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients with Chronic Lymphocytic Leukaemia
-een van de auteurs: internist-hematoloog mw. F. de Boer
Blood (2022) 140 (Supplement 1): 7020–7022.
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
-een van de auteurs: internist-hematoloog mw. F. de Boer
Lancet Haematol. 2022 Mar;9(3):e190-e199. doi: 10.1016/S2352-3026(22)00034-5. PMID: 35240075
Pneumo-CLL-studie: immunogeniciteit van het aanbevolen pneumokokken vaccinatieschema bij patiënten met chronische lymfatische leukemie
-een van de auteurs: internist-hematoloog mw. F. de Boer
Nederlands tijdschrift voor Hematologie special juli 2021
MRD-guided or fixed 12 cycles of venetoclax consolidation after venetoclax plus obinutuzumab treatment in first-line FCR unfit patients with CLL: primary endpoint analysis of the HOVON 139/GiVe trial
-een van de auteurs: internist-hematoloog mw. F. de Boer
European Hematology Association oral presentation 2021
Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study
-een van de auteurs: internist-hematoloog mw. F. de Boer
Leuk Lymphoma. 2020 Nov;61(11):2752-2755. doi: 10.1080/10428194.2020.1775217. Epub 2020 Jun 12.
Invasive fungal infections in patients treated with Bruton's tyrosine kinase inhibitors.
-een van de auteurs: internist-hematoloog mw. F. de Boer
Neth J Med. 2020 Sep;78(5):294-296.PMID: 3309325
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study
-een van de auteurs: internist-hematoloog mw. F. de Boer
Exp Hematol. 2020 Sep: 89:55-60.e6. doi: 10.1016/j.exphem.2020.08.002. Epub 2020 Aug 8.
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study
-een van de auteurs: internist-hematoloog mw. F. de Boer
Mycoses. 2019 Dec;62(12):1140-1147. doi: 10.1111/myc.13001. Epub 2019 Oct 22.
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia
-een van de auteurs: internist-hematoloog mw. F. de Boer
Leukemia. 2019 Feb;33(2):390-402. doi: 10.1038/s41375-018-0215-9. Epub 2018 Jul 23.
Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia
-een van de auteurs: internist-hematoloog mw. F. de Boer
Haematologica. 2019 Jan;104(1):147-154. doi: 10.3324/haematol.2018.193854. Epub 2018 Aug 16.
Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL
-een van de auteurs: internist-hematoloog mw. F. de Boer
Blood Adv. 2018 Dec 26;2(24):3566-3571. doi: 10.1182/bloodadvances.2018019422.
First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment
-een van de auteurs: internist-hematoloog mw. F. de Boer
Blood 2018 , Volume 132 (Supplement 1) 29 November 2018, Page 1860
Gastric actinomycosis facilitated by diffuse large B-cell lymphoma
-een van de auteurs: internist-hematoloog mw. F. de Boer
Int J. CAse Rep Images 2018, 9 : doi:10.5348/100965Z01RS2018CR
Efficacy and Safety of First-Line Therapy with Chlorambucil, Rituximab and Individualized Dose Lenalidomide in FCR-Unfit Patients with Advanced Chronic Lymphocytic Leukemia (CLL): A Phase I/II HOVON Trial
-een van de auteurs: internist-hematoloog mw. F. de Boer
Blood 2017, Volume 130 (Supplement 1) 8 December 2017, Page 4328
Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia
-een van de auteurs: internist-hematoloog mw. F. de Boer
Leuk Lymphoma. 2015;56(8):2439-47. doi: 10.3109/10428194.2014.996751. Epub 2015 Jan 21.
Een “gewone” bellse parese. All that palsies is not Bell’s
-een van de auteurs: internist-hematoloog mw. F. de Boer
Tijdschrift voor Neurol Neurochir 2015: 116 (4): 217-222
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme
-een van de auteurs: internist-hematoloog mw. F. de Boer
Br. Journal of Heaematology 2011 : 155 (5) :599-606
Huidafwijkingen als eerste teken van macroglobulinemie van Waldenström
-een van de auteurs: internist-hematoloog mw. F. de Boer
Ned Tijdschr Geneeskd 2010;154:A2097
Early apoptosis largely accounts for functional impairment of CD34+ cells in frozen-thawed stem cell grafts
-een van de auteurs: internist-hematoloog mw. F. de Boer
J Hematother Stem Cell Res. 2002 Dec;11(6):951-63. doi: 10.1089/152581602321080619.
Extensive early apoptosis in frozen–thawed CD34-positive stem cells decreases threshold doses for haematological recovery after autologous peripheral blood progenitor cell transplantation
-een van de auteurs: internist-hematoloog mw. F. de Boer
Bone Marrow Transplantation 2002, 29 (13) 249-255
Homing and clonogenic outgrowth of CD34(+) peripheral blood stem cells: a role for L-selectin?
-een van de auteurs: internist-hematoloog mw. F. de Boer
Exp Hematol. 2002 Jun;30(6):590-7. doi: 10.1016/s0301-472x(02)00797-x.
Large populations of non-clonogenic early apoptotic CD34-positive cells are present in frozen-thawed peripheral blood stem cell transplants
-een van de auteurs: internist-hematoloog mw. F. de Boer
Bone Marrow Transplantation 2001 27 487-498
The phenotypic profile of CD34-positive peripheral blood stem cells in different mobilization regimens
-een van de auteurs: internist-hematoloog mw. F. de Boer
British Journal of Haematology 2000, 11 (4): 1138-1144.
Changes in L-selectin expression on CD34-positive cells upon cryopreservation of peripheral blood stem cell transplants
-een van de auteurs: internist-hematoloog mw. F. de Boer
Bone Marrow Transplantation 1998; 22 : 1103-1110.

Onderzoek in Ikazia - Interne geneeskunde - Boer

Publicaties internist-hematoloog mw. dr. F. de Boer